News & Media

Introducing n-Lorem Foundation – Creating a better future for ultra-rare, one patient at a time

n-Lorem Foundation is the first and only non-profit organization to charitably provide personalized antisense oligonucleotide (ASO) treatments to patients with ultra-rare diseases (1-30 patients, worldwide) – for free, for life.

Before the pioneering work that created the technology n-Lorem uses today, infants like Cameron Harding would have succumbed to their diseases within 6 months of life. Now, n-Lorem is on a mission to provide families with immediate hope, rapid treatment, and another chance for their babies to grow into healthy children. n-Lorem is the bridge that connects the needs of ultra-rare patients to the engine of hope, which is the ASO technology invented at Ionis Pharmaceuticals – a proven technology that has been studied in thousands of patients.

We are using a charitable model to solve what a commercial model cannot. We can’t do it alone. The more help we have and the more money we raise, the more lives we can save – together. To learn more about the n-Lorem Foundation, visit, and follow us on Twitter, Facebook and LinkedIn. About n-Lorem Foundation The n-Lorem Foundation is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients with ultra-rare diseases (1 to 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. ASOs are short strands of modified DNA that can specifically target the transcripts of a defective gene to correct the abnormality. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Stanley T. Crooke, M.D., Ph.D., former chairman and CEO, and executive chairman of the board of Ionis Pharmaceuticals, who founded Ionis Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics.